Mantle cell lymphoma: 2017 update on diagnosis, risk‐stratification, and clinical management

Disease Overview Mantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4‐5 years. Diagnosis Diagnosis is based on lymph node, bone...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2017-08, Vol.92 (8), p.806-813
1. Verfasser:	Vose, Julie M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis inhibitors Autografts Bone marrow Bortezomib Bruton's tyrosine kinase Chemotherapy Clinical trials Combined Modality Therapy Cyclin D1 Cytology Cytotoxicity Differential diagnosis Disease Management Drug Resistance, Neoplasm Enzyme inhibitors Hematology Humans Immunohistochemistry Lymph nodes Lymphocytes Lymphoma Lymphoma, Mantle-Cell - diagnosis Lymphoma, Mantle-Cell - etiology Lymphoma, Mantle-Cell - mortality Lymphoma, Mantle-Cell - therapy Mantle cell lymphoma Monoclonal antibodies NF-κB protein Non-Hodgkin's lymphoma Prognosis Protein-tyrosine kinase Recurrence Remission Risk Assessment Risk Factors Risk groups Rituximab Spleen Stem cell transplantation Stem cells Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!